Canada Life’s Pacira BioSciences PCRX Stock Holding History

Canada Life’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$746K	Sell	33,005 -3,323	-9%	-$73.8K	﹤0.01%	1425
2025 Q4	$940K	Sell	36,328 -4,575	-11%	-$109K	﹤0.01%	1399
2025 Q3	$1.03M	Buy	40,903 +3,935	+11%	+$96.7K	﹤0.01%	1436
2025 Q2	$883K	Sell	36,968 -1,514	-4%	-$38.2K	﹤0.01%	1468
2025 Q1	$956K	Sell	38,482 -29,167	-43%	-$698K	﹤0.01%	1451
2024 Q4	$1.27M	Sell	67,649 -5,135	-7%	-$90.2K	﹤0.01%	1410
2024 Q3	$1.1M	Buy	72,784 +24,826	+52%	+$424K	﹤0.01%	1489
2024 Q2	$1.37M	Buy	47,958 +8,729	+22%	+$248K	﹤0.01%	1425
2024 Q1	$1.15M	Buy	39,229 +2,455	+7%	+$75.4K	﹤0.01%	1470
2023 Q4	$1.24M	Sell	36,774 -8,469	-19%	-$248K	﹤0.01%	1437
2023 Q3	$1.39M	Buy	45,243 +5,296	+13%	+$191K	﹤0.01%	1369
2023 Q2	$1.6M	Sell	39,947 -11,845	-23%	-$490K	﹤0.01%	1309
2023 Q1	$2.11M	Buy	51,792 +5,025	+11%	+$200K	0.01%	1207
2022 Q4	$1.81M	Sell	46,767 -3,632	-7%	-$177K	﹤0.01%	1279
2022 Q3	$2.68M	Buy	50,399 +5,700	+13%	+$317K	0.01%	1010
2022 Q2	$2.61M	Buy	44,699 +6,193	+16%	+$406K	0.01%	1024
2022 Q1	$3.02M	Buy	38,506 +146	+0.4%	+$9.73K	0.01%	986
2021 Q4	$2.3M	Buy	38,360 +522	+1%	+$28.8K	﹤0.01%	1123
2021 Q3	$2.13M	Hold	37,838	–	–	0.01%	1142
2021 Q2	$2.3M	Buy	37,838 +74	+0.2%	+$4.68K	0.01%	1067
2021 Q1	$2.65M	Sell	37,764 -4,419	-10%	-$316K	0.01%	957
2020 Q4	$2.52M	Sell	42,183 -4,770	-10%	-$279K	﹤0.01%	1022
2020 Q3	$2.82M	Sell	46,953 -4,064	-8%	-$236K	0.01%	907
2020 Q2	$2.67M	Sell	51,017 -3,914	-7%	-$164K	0.01%	937
2020 Q1	$1.84M	Buy	54,931 +4,239	+8%	+$176K	﹤0.01%	992
2019 Q4	$2.28M	Buy	+50,692	New	+$2.15M	0.01%	1049
2019 Q3	–	Sell	-3,709	Closed	-$161K	–	1937
2019 Q2	$161K	Sell	3,709 -1,655	-31%	-$70.3K	﹤0.01%	2085
2019 Q1	$204K	Hold	5,364	–	–	﹤0.01%	1872
2018 Q4	$222K	Buy	5,364 +1,529	+40%	+$71.4K	﹤0.01%	1905
2018 Q3	$188K	Hold	3,835	–	–	﹤0.01%	1997
2018 Q2	$123K	Hold	3,835	–	–	﹤0.01%	2124
2018 Q1	$120K	Hold	3,835	–	–	﹤0.01%	2112
2017 Q4	$175K	Hold	3,835	–	–	﹤0.01%	2002
2017 Q3	$148K	Hold	3,835	–	–	﹤0.01%	2036
2017 Q2	$182K	Hold	3,835	–	–	﹤0.01%	1942
2017 Q1	$174K	Hold	3,835	–	–	﹤0.01%	1948
2016 Q4	$124K	Hold	3,835	–	–	﹤0.01%	2053
2016 Q3	$131K	Hold	3,835	–	–	﹤0.01%	2033
2016 Q2	$129K	Hold	3,835	–	–	﹤0.01%	2017
2016 Q1	$203K	Hold	3,835	–	–	﹤0.01%	1304
2015 Q4	$295K	Hold	3,835	–	–	﹤0.01%	1084
2015 Q3	$158K	Hold	3,835	–	–	﹤0.01%	1382
2015 Q2	$271K	Buy	3,835 +1,300	+51%	+$102K	﹤0.01%	1206
2015 Q1	$224K	Hold	2,535	–	–	﹤0.01%	1290
2014 Q4	$224K	Hold	2,535	–	–	﹤0.01%	1246
2014 Q3	$247K	Buy	2,535 +835	+49%	+$81.2K	﹤0.01%	1134
2014 Q2	$156K	Hold	1,700	–	–	﹤0.01%	1282
2014 Q1	$118K	Hold	1,700	–	–	﹤0.01%	1354
2013 Q4	$98K	Buy	+1,700	New	+$89.4K	﹤0.01%	1420

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Canada Life's PCRX Position: Q1 2026 in Review

Canada Life reduced its Pacira BioSciences (PCRX) stake by 9.1% in Q1 2026, selling an estimated $73.8K and leaving 33,005 shares worth $746K. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

Canada Life first reported a position in PCRX in Q4 2013 and has held it in 49 quarters since. The position peaked at $3.02M in Q1 2022. 241 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Canada Life held 33,005 shares of Pacira BioSciences worth $746K as of Q1 2026.
Canada Life sold 3,323 Pacira BioSciences shares in Q1 2026, an estimated $73.8K.
Pacira BioSciences made up ﹤0.01% of Canada Life's portfolio in Q1 2026, its #1425 holding.
Canada Life first reported a position in Pacira BioSciences in Q4 2013 and has held it in 49 quarters since.
Canada Life's Pacira BioSciences position peaked at $3.02M in Q1 2022.
241 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Canada Life's 13F filing for Q1 2026, filed 14 May 2026.